ArticleNucleic acids research2016
Insights into RNA binding by the anticancer drug cisplatin from the crystal structure of cisplatin-modified ribosome.
Article in Nucleic acids research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Synergistic Anticancer Activity ofCells · 2026Article
- Transcriptome-wide mapping reveals an RNA-dependent mechanism of platinum cancer drugs.bioRxiv : the preprint server for biology · 2025Article
- Reversing the Irreversible: miRNA-Targeting Mesyl Phosphoramidate Oligonucleotides Restore Sensitivity to Cisplatin and Doxorubicin of KB-8-5 Epidermoid Carcinoma Cells.Biomedicines · 2025Article
- Collision-induced ribosome degradation driven by ribosome competition and translational perturbations.Nature communications · 2025Article
- RNA damage and its implications in genome stability.DNA repair · 2025Review
- Article
- Modulating Macrophage Polarization for Severe Acute Pancreatitis Therapy via Cisplatin-like Prussian Blue Nanozymes.Theranostics · 2025Article
- The Interplay Between theInternational journal of molecular sciences · 2024Review
- Ribosome Assembly and Repair.Annual review of cell and developmental biology · 2024Review
- Identification of protein biomarkers for prediction of response to platinum-based treatment regimens in patients with non-small cell lung cancer.Molecular oncology · 2024Article
- Bioorthogonal Chemistry in Cellular Organelles.Topics in current chemistry (Cham) · 2023Review
- Stress-responsive Gdf15 counteracts renointestinal toxicity via autophagic and microbiota reprogramming.Communications biology · 2023Article
- Sea urchin (Diadema savignyi) extract as a novel protective agent against cisplatin induced neurotoxicity in rats.BMC pharmacology & toxicology · 2023Article
- Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel.Annals of medicine · 2023Article
- RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures.Cancer cell international · 2022Article
- Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance.Nature communications · 2022Article
- LyeTxI-b, a Synthetic Peptide Derived From a Spider Venom, Is Highly Active in Triple-Negative Breast Cancer Cells and Acts Synergistically With Cisplatin.Frontiers in molecular biosciences · 2022Article
- Translation inhibition and suppression of stress granules formation by cisplatin.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Article
- Development, validation, and application of the ribosome separation and reconstitution system for protein translation in vitro.RNA (New York, N.Y.) · 2021Article
- The Effect of SLC2A3 Expression on Cisplatin Resistance of Colorectal Cancer Cells.Iranian journal of public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cisplatin is a widely prescribed anticancer drug, which triggers cell death by covalent binding to a broad range of biological molecules. Among cisplatin targets, cellular RNAs remain the most poorly characterized molecules. Although cisplatin was shown to inactivate essential RNAs, including ribosomal, spliceosomal and telomeric RNAs, cisplatin binding sites in most RNA molecules are unknown, and therefore it remains challenging to study how modifications of RNA by cisplatin contributes to its toxicity. Here we report a 2.6Å-resolution X-ray structure of cisplatin-modified 70S ribosome, which describes cisplatin binding to the ribosome and provides the first nearly atomic model of cisplatin-RNA complex. We observe nine cisplatin molecules bound to the ribosome and reveal consensus structural features of the cisplatin-binding sites. Two of the cisplatin molecules modify conserved functional centers of the ribosome-the mRNA-channel and the GTPase center. In the mRNA-channel, cisplatin intercalates between the ribosome and the messenger RNA, suggesting that the observed inhibition of protein synthesis by cisplatin is caused by impaired mRNA-translocation. Our structure provides an insight into RNA targeting and inhibition by cisplatin, which can help predict cisplatin-binding sites in other cellular RNAs and design studies to elucidate a link between RNA modifications by cisplatin and cisplatin toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.